Tildacerfont
Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency
Spruce BiosciencesSmall moleculePhase 2Active
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 23/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hydrocortisone Neurocrine UK Limited | Phase 1/2 | NR |
Same molecule, other indications
Tildacerfont is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →